{"id":789161,"date":"2023-10-10T07:33:11","date_gmt":"2023-10-10T11:33:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\/"},"modified":"2023-10-10T07:33:11","modified_gmt":"2023-10-10T11:33:11","slug":"monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\/","title":{"rendered":"Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WILMETTE, Ill., Oct.  10, 2023  (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Andrew J. Cittadine, Monopar\u2019s Chief Operating Officer, will present at the Roth MKM 2023 Healthcare Opportunities Conference.<\/p>\n<p>\n        <strong><br \/>\n          <em>Presentation Details:<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>Date: October 12, 2023<br \/>Time: 12:15 p.m. (ET)<br \/>Location: The Yale Club, New York City, New York<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IVhC11SPfB4z3v1DEhfwqC9p93Hcw-jkLG1OrJgqXKTuWIXl1HpTFI1dNgUcB7l2TZVhLQyWzkLk9IrMbs1Xlu4QRQW-y8CqzI-5UdYqShGiTEqMl77HgDUm8hXruXrDrw6BYhUCQDU2vZEkrE_LlHmNXHBtBYH-6xY9jCDuZynhCXAFNaTJwA2-pc3Z-67s\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.roth.com\/conferences\/upcoming-conferences<\/a>\n      <\/p>\n<p>\n        <strong>About Monopar Therapeutics Inc.<\/strong>\n      <\/p>\n<p>Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar&#8217;s pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma\u037e MNPR-101, a late-stage preclinical antibody for radiopharmaceutical use in advanced cancers\u037e and MNPR-202, an early-stage camsirubicin analog for various cancers. For more information, visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hyQX2opLLk3SxHxfwQr9S-w1liFfJDNwD7-_0TeACAgm-SjY-_pZuX-nThNLp_ULYc9wIeapfz2MJhhb7jErqLWV-LAvdF2N3xRKXY5fBj5P5FRmc7-OO757Vj00xXccR2JMf_sQqF73tQjc1FDJLXGCvhpQTXv-h0zoO6ZhA8ClY1wmxrOYH4iC5Gt91YnpI06oBFGVAUi_RYLF98nHf2u4yIf1QvSJiQ-RDCatGWpBf1bRYjMIco6Hyz0SIBFetIgpwvIkmXenW8yVPYwBfF_AZlTOILf7j7bhrMvAG4TKfYJmyOsuTrXvzmGbU4Q3fy_SNNmEsVQPTBUZJ8p2ko0oOItG0fhWpDk0Z6U8FTu_sCXT8K2OP0vmZKcLVVk_497i_0rI5nbW_YUL1bFz51gv69zTt1sa3X7YfpiPiFE=\" rel=\"nofollow noopener\" target=\"_blank\">www.monopartx.com<\/a>.<\/p>\n<p>\n        <strong>CONTACT:<\/strong>\n      <\/p>\n<p>\n        <strong>Monopar Therapeutics Inc.<\/strong><br \/>\n        <br \/>Investor Relations<br \/>Kim R. Tsuchimoto<br \/>Chief Financial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9XhPcv4SJvG5Cn09lHW2BWL9Mw8VWAOlH0y6VZ9WEU00KzrvWusPt4eaDzSd0mfme9xZ7tbGzGyIc1zuoGmq2RmZ-QGvVAx5y6QB4IEYIcOWWb686d-j_oOnBvcnb8iihnR4S3yikANcH-X5_kQJcGCXRpfYJdX7ZW_H7GTZx5Fryp_hMW1mQFxVZ9ueC1TQEvhUjf7Bjm02FWKWOOsqdPXg7Ha5bSGqr1hLqh9MMzN5tmldTXhYVeDJxGUjvESeGaq6BgC58iEZlRtQLZi6Pw==\" rel=\"nofollow noopener\" target=\"_blank\"><u>kimtsu@monopartx.com<\/u><\/a><\/p>\n<p>Follow Monopar on social media for updates:<br \/>Twitter: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_811zVRxImqfPTLC0d2vNoZzy6Q_7jWExBwcut6F0LDk23WnRav4Hsfiphm1lUejVEd20S8yiONA_YdJVN30wQVsh5t0zRZmDrCWJv2Mz22Xj_CdLZWD5dbJq0muD_Sn8QKSkiKRtnwRrgK9FHDrBfNr4zxHwlwbebR8VQquMEPrttHz9v0pTtQc38-9GfQcTiPV0mRqoghblryrZasK56vfZ75PKm6HYfT4cOl3ya4=\" rel=\"nofollow noopener\" target=\"_blank\"><u>@MonoparTx<\/u><\/a>\u2009LinkedIn: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pAewn7XLZhIi4krq12e5OuQBjWATEq0uiTAi3lA0Yk6hbqL4bptanw16q4kP6CPqUHCeDPCT5S0zlBDCOLbyGE9U8PbGfI11xQKO7UFiA00hWOKCvcfIRr35U2DDgMtC1--6qyZ2DPLSDaP3PdmXhwNxnaUoVc5_RVmfezSfHXpUDZiMRIU6AUNxLxg1kz3B52vK9sc4_h0rVd_JSOcw5WgtOPkvL9P76h6KiSLgKbzxpY7Z57kaUugywZyCKJcad1MqFen-Su6O2xVPbUH4juoCExSfMxCBlXJij7Ch-5Ni7Lh0bsVGSH2kujXykbSo\" rel=\"nofollow noopener\" target=\"_blank\"><u>Monopar Therapeutics<\/u><\/a><\/p>\n<p>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MzI4MSM1ODU2MDMyIzIxOTM4NjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OGI4NzUxNjMtNjRmYS00NzhiLWE5OGMtMjlkNDk0MTYzOWFmLTEyMDU0MTY=\/tiny\/Monopar-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WILMETTE, Ill., Oct. 10, 2023 (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Andrew J. Cittadine, Monopar\u2019s Chief Operating Officer, will present at the Roth MKM 2023 Healthcare Opportunities Conference. Presentation Details: Date: October 12, 2023Time: 12:15 p.m. (ET)Location: The Yale Club, New York City, New York https:\/\/www.roth.com\/conferences\/upcoming-conferences About Monopar Therapeutics Inc. Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar&#8217;s pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma\u037e MNPR-101, a late-stage preclinical antibody for radiopharmaceutical use in advanced cancers\u037e and MNPR-202, an early-stage camsirubicin analog for various cancers. For more information, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-789161","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WILMETTE, Ill., Oct. 10, 2023 (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Andrew J. Cittadine, Monopar\u2019s Chief Operating Officer, will present at the Roth MKM 2023 Healthcare Opportunities Conference. Presentation Details: Date: October 12, 2023Time: 12:15 p.m. (ET)Location: The Yale Club, New York City, New York https:\/\/www.roth.com\/conferences\/upcoming-conferences About Monopar Therapeutics Inc. Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar&#8217;s pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma\u037e MNPR-101, a late-stage preclinical antibody for radiopharmaceutical use in advanced cancers\u037e and MNPR-202, an early-stage camsirubicin analog for various cancers. For more information, &hellip; Continue reading &quot;Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-10T11:33:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MzI4MSM1ODU2MDMyIzIxOTM4NjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference\",\"datePublished\":\"2023-10-10T11:33:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\\\/\"},\"wordCount\":162,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0MzI4MSM1ODU2MDMyIzIxOTM4NjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\\\/\",\"name\":\"Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0MzI4MSM1ODU2MDMyIzIxOTM4NjM=\",\"datePublished\":\"2023-10-10T11:33:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0MzI4MSM1ODU2MDMyIzIxOTM4NjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0MzI4MSM1ODU2MDMyIzIxOTM4NjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\/","og_locale":"en_US","og_type":"article","og_title":"Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference - Market Newsdesk","og_description":"WILMETTE, Ill., Oct. 10, 2023 (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Andrew J. Cittadine, Monopar\u2019s Chief Operating Officer, will present at the Roth MKM 2023 Healthcare Opportunities Conference. Presentation Details: Date: October 12, 2023Time: 12:15 p.m. (ET)Location: The Yale Club, New York City, New York https:\/\/www.roth.com\/conferences\/upcoming-conferences About Monopar Therapeutics Inc. Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar&#8217;s pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma\u037e MNPR-101, a late-stage preclinical antibody for radiopharmaceutical use in advanced cancers\u037e and MNPR-202, an early-stage camsirubicin analog for various cancers. For more information, &hellip; Continue reading \"Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-10-10T11:33:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MzI4MSM1ODU2MDMyIzIxOTM4NjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference","datePublished":"2023-10-10T11:33:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\/"},"wordCount":162,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MzI4MSM1ODU2MDMyIzIxOTM4NjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\/","name":"Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MzI4MSM1ODU2MDMyIzIxOTM4NjM=","datePublished":"2023-10-10T11:33:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MzI4MSM1ODU2MDMyIzIxOTM4NjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MzI4MSM1ODU2MDMyIzIxOTM4NjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-roth-mkm-2023-healthcare-opportunities-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/789161","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=789161"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/789161\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=789161"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=789161"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=789161"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}